Condition: Alopecia · Chemotherapy-induced Alopecia · Hair Loss · Sponsor: Cooler Heads Care Inc.
The purpose of this prospective study is to assess the ability of AMMA to prevent hair loss in women receiving chemotherapy (CT) for early-stage breast cancer. Additionally, the purpose is also to assess the safety, tolerability and compliance, quality of life, and satisfaction with hair preservation after CT treatment.
This description comes directly from the study's public registry record.
Chris Schultz, BS · 9715067552 · cschultz@ecr-inc.com
Always discuss trial participation with your own doctor first.
| University of Arizona | Tucson, Arizona, United States | Recruiting |
| Carle Health | Urbana, Illinois, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05484973